Treatment of alopecia areata with diphenylcyclopropenone

Steen, P.H.M. van der; Baar, H.M.J. van; Perret, C.; Happle, Rudolf

doi:10.1016/0190-9622(91)70037-3

Cited by 95 publications

(59 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Few treatments have been subjected to randomized controlled trials and, except for contact immunotherapy, there are few studies with long-term follow-up. [5][6][7][8][9][10][11] Most of the follow-up studies consider only severe degrees of AA and disregard milder disease, their treatment, and prognosis. 12 Familial history of autoimmune disease, personal history of atopy, severe hair loss, onset in childhood, and nail abnormalities have been associated with a poor prognosis.…”

mentioning

confidence: 99%

Alopecia areata: A long term follow-up study of 191 patients

Tosti

Bellavista

Iorizzo

2006

Journal of the American Academy of Dermatology

253

212

View full text Add to dashboard Cite

mentioning

confidence: 99%

Alopecia areata: A long term follow-up study of 191 patients

Tosti

Bellavista

Iorizzo

2006

Journal of the American Academy of Dermatology

253

212

View full text Add to dashboard Cite

“…Minoxidil or anthralin was also reported to elicit cosmetically acceptable hair regrowth in some less severe cases [6,7,8,9]. In chronic severe AA, topical immunotherapy is considered to be the most effective and accepted therapeutic modality [10,11,12,13,14]. Although a wide range of response rates has been reported, topical immunotherapy using dinitrochlorobenzene, squaric acid dibutyl ester, and diphenylcyclopropenone succeeded in achieving cosmetically acceptable hair regrowth in significant numbers of patients.…”

Section: Introductionmentioning

confidence: 99%

A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

et al. 2006

View full text Add to dashboard Cite

Background: Systemic corticosteroids are one of the most commonly used therapeutic modalities for patients with extensive alopecia areata (AA), although they entail several drawbacks. Objective: To determine the best modality for systemic corticosteroid use in terms of their efficacy, relapse rate, and side effects. Methods: Fifty-one patients with single or multiple AA (AA/multiplex) and 38 patients with alopecia totalis or AA universalis (AA totalis/universalis) were enrolled in this open study. They were randomly divided into three groups depending on the time of their initial visit. They were administered (1) oral dexamethasone (Dex) 0.5 mg/day for 6 months (Dex group), (2) intramuscular triamcinolone acetonide (imTA) 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year (imTA group), and (3) pulse therapy (PT) using oral predonine 80 mg for 3 consecutive days once every 3 months (PT group). After the treatment, each treatment modality was evaluated by the response rate, relapse rate, and side effect profile. Results: The response rate of AA/multiplex was significantly better in the imTA group than in the Dex group. The overall relapse rate and that of AA totalis/universalis were significantly better in the PT group than in the Dex group. Dysmenorrhea was the most common and problematic side effect. Impairment of the adrenocortical reserve was seen in 7% of the PT group and 23% of the imTA group, which was recov ered without any further medical treatment. Conclusion: imTA or pulse therapy is effective for AA and has an acceptable level of side effects. The development of a new strategy to reduce the relapse rate is needed.

show abstract

“…Topical immu notherapy was carried out according to standardized procedures. 10,14 Hair regrowth was recorded as follows: if some regrowth of hair occurred the response was designated as 'hair growth', and if the regrowth was complete the response was recorded as 'complete hair growth'.…”

Section: Methodsmentioning

confidence: 99%

“…The details of patients treated with DCP have been reported previously. 10,14 Dapsone was started at a daily dosage of 100 mg. If side-effects such as nausea, headache, sleep disturb ance, anaemia or methaemoglobinaemia occurred, the dosage was reduced to 50 mg daily, or the drug was stopped.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Dapsone versus topical immunotherapy in alopecia areata

1995

View full text Add to dashboard Cite

Summary Twenty‐seven patients with severe alopecia areata were treated with dapsone. The results of a mean treatment duration of 10±0.5 months are reported, and compared with the results of long‐term topical immunotherapy obtained previously at the same institute. The efficacy of dapsone proved to be markedly inferior to that of topical immunotherapy. The percentage of patients showing regrowth of hair during treatment with dapsone was comparable with the occurrence of spontaneous regrowth of hair reported in the literature.

show abstract

Treatment of alopecia areata with diphenylcyclopropenone

Cited by 95 publications

References 17 publications

Alopecia areata: A long term follow-up study of 191 patients

Alopecia areata: A long term follow-up study of 191 patients

A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

Dapsone versus topical immunotherapy in alopecia areata

Contact Info

Product

Resources

About